H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Clinical trial NCT07501156 · RECRUITING

Trial details

NCT number: NCT07501156
Sponsor: Shenzhen Geno-Immune Medical Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma

Start date: 2026-03-18
Primary completion: 2029-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.